As cardiovascular and cerebrovascular diseases remain a major cause of death globally, it is necessary to identify all their risk factors to improve public health and reduce their societal burden.
As cardiovascular and cerebrovascular diseases remain a major cause of death globally, it is necessary to identify all their risk factors to improve public health and reduce their societal burden.
Even though the prognosis after myocardial infarction (MI) has improved much over recent decades due to improved and faster revascularization, platelet inhibition, and device therapy, a proportion of post-acute MI (AMI) patients with additional risk factors remain at high risk, with 5-year mortality ranging from 15% to 45% depending on the population.
Pp to 30% of the patients with decompensated HF (NYHA classification III to IV) present with LDs resistance.
Patients with Multisite artery disease (MSAD) are regularly encountered in clinical practice and their prognosis is poorer than that of patients with just one territory affected.
Global estimates show that a large proportion of society worldwide (31% of adults) had Stage 2 hypertension (>140/90 mmHg) in 2010.